Micreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch
THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...
mehr